Biofrontera Inc. filings document a Nasdaq-listed dermatology biopharmaceutical company focused on photodynamic therapy. The company’s Form 8-K reports cover financial results, preliminary revenue updates, clinical disclosures for Ameluz PDT programs, patent-related proceedings, and Nasdaq continued-listing compliance notices. Its registered securities include common stock under BFRI and warrants under BFRIW.
Proxy materials describe board elections, stockholder voting matters, equity incentive plan approvals, auditor ratification, and governance procedures. The filing record also reflects disclosure controls around non-GAAP financial measures, Regulation FD announcements, risk-related litigation and patent matters, and capital-structure items such as warrants and preferred stock purchase rights.
John J. Borer III, a director of Biofrontera Inc. (BFRI), reported a non-derivative change dated 07/22/2025. The filing shows an employee stock option transaction: 20,000 options with a $1 exercise price, exercisable on 07/22/2025 and expiring on 07/22/2035. Following the reported transaction, 20,000 shares of common stock are shown as beneficially owned directly. The option vests in twelve equal monthly installments beginning 08/22/2025. The form is signed by Daniel Hakansson as attorney-in-fact for Mr. Borer on 09/16/2025.